Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28793735 | 0.88 | CHRNB2 (0.38) | CYP11B1CYP11B2DAOIDH1CHRNB2 | |
| SCHEMBL3749196 | 0.84 | CYP11B1 (0.43) | CYP11B1CYP11B2DAOCYP3A4CYP2C9 | |
| SCHEMBL24680657 | 0.81 | HCAR2 (0.38) | CYP11B1CYP11B2HCAR2AR | |
| SCHEMBL30879971 | 0.81 | HCAR2 (0.38) | CYP11B1CYP11B2HCAR2AR | |
| SCHEMBL30165101 | 0.79 | CYP11B1 (0.37) | CYP11B1CYP11B2GPR55DAOIDH1 | |
| SCHEMBL6371572 | 0.78 | HCAR2 (0.39) | CYP11B1CYP11B2HCAR2KIF11 | |
| SCHEMBL21744244 | 0.77 | CYP11B2 (0.56) | CYP11B1CYP11B2GPR55IDH1KIF11 | |
| SCHEMBL56635 | 0.74 | — | — | |
| SCHEMBL16230231 | 0.73 | CYP3A4 (0.38) | CYP11B1CYP11B2DAOIDH1CYP3A4 | |
| SCHEMBL5700171 | 0.73 | CYP11B1 (0.38) | CYP11B1CYP11B2DAOIDH1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-113200962-B | Phenylimidazole compounds | 株式会社大塚制药工场 | 2024-10-18 | — | — | CN | disclosed |
| US-20240284907-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2024-08-29 | — | — | US | disclosed |
| EP-4415706-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024165050-A1 | PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD | AUBRAK THERAPEUTICS (CN) | 2024-08-15 | — | — | WO | disclosed |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| EP-4347023-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | Disc Medicine, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-2934538-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015020112-A1 | DIFLUOROMETHYLENE COMPOUND | 石原産業株式会社 (JP) | 2015-02-12 | — | — | WO | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| CN-103415515-A | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORP | 2013-11-27 | — | — | CN | disclosed |
| WO-2013127913-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | ROTTAPHARM S.P.A. (IT) | 2013-09-06 | — | — | WO | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049174-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-A]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-4775762-A | INSECTICIDES | THE DOW CHEMICAL COMPANY (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0003278-A1 | Polysubstituted-2-(3-loweralkylamino-2-R0-propoxy)pyridines, process for preparing the same, and pharmaceutical compositions containing the same | MERCK & CO. INC. (US) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | CYP11B1 4507/4885CYP11B2 4477/4885HCAR2 2641/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | CYP11B1 521/4885CYP11B2 485/4885HCAR2 3885/4885 |
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | CYP11B1 473/4885CYP11B2 761/4885HCAR2 1294/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | CYP11B1 4489/4885CYP11B2 4459/4885HCAR2 2609/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | CYP11B1 120/4885CYP11B2 151/4885HCAR2 202/4885 |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | CYP11B1 2934/4885CYP11B2 2071/4885HCAR2 442/4885 |
| US-20240284907-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | DDT, DDC, GLUL | CYP11B1 4152/4885CYP11B2 3948/4885HCAR2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.